Trinity Biotech PLC Schedule 13D activist filings

Perceptive Advisors LLC, along with its affiliates, has amended its Schedule 13D filing concerning Trinity Biotech plc, detailing changes to a convertible note and credit agreement.

Perceptive Credit Holdings II, L.P. sold nearly 2 million American Depositary Shares of Trinity Biotech plc between December 2025 and January 2026, with prices declining significantly.

Perceptive Advisors and its funds have amended credit agreements with Trinity Biotech plc, converting significant debt obligations into potentially convertible equity, subject to a 9.9% beneficial ownership cap.

DAYLI Filers report complete divestment of their beneficial ownership in Trinity Biotech plc following the 2025 MiCo IVD Purchase by AI n M.

An amendment to Schedule 13D reports a change in MiCo IVD's management and confirms its 17.0% beneficial ownership in Trinity Biotech plc.

AI n M net Ltd. has acquired MiCo IVD Holdings, LLC, making it a significant beneficial owner of 17.0% of Trinity Biotech plc's Class 'A' Ordinary Shares.

Perceptive entities propose converting significant debt and contingent obligations of Trinity Biotech plc into equity, aiming to reduce cash outflows for the issuer.

Perceptive Advisors LLC and its affiliated entities have filed an Amendment No. 4 to their Schedule 13D, disclosing a combined beneficial ownership of 19.8% in Trinity Biotech plc, including exercisable warrants.

Perceptive Advisors and its affiliates have filed an amended Schedule 13D, revealing a combined beneficial ownership of 20.9% in Trinity Biotech plc, including shares from warrant exercises.